RNA related markers of thyroid cancer

doi:10.3760/cma.j.issn.1673-422X.2017.07.014

Abstract

Chen Lili, Lan Kuixu. RNA related markers of thyroid cancer[J]. Journal of International Oncology, 2017, 44(7): 534-536.

［1］ Kim WB. A closer look at papillary thyroid carcinoma［J］. Endocrinol Metab (Seoul), 2015, 30(1): 1-6. DOI: 10.3803/EnM.2015.30.1.1. ［2］ Bisof V, Rakusic Z, Despot M. Treatment of patients with anaplastic thyroid cancer during the last 20 years: whether any progress has been made?［J］. Eur Arch Otorhinolaryngol, 2015, 272(7): 1553-1567. DOI: 10.1007/s00405-014-3108-1. ［3］ Sung JY, Na DG, Kim KS, et al. Diagnostic accueacy of fineneedle aspiration versus coreneedle biopsy for the diagnosis of thyroid malignancy in a clinical cohort［J］. Eur Radiol, 2012, 22(7): 15641572. DOI: 10.1007/s0033001224056. ［4］ Renshaw AA. Significance of repeatedly nondiagnostic thyroid fineneedle aspirations［J］. Am J Clin Pathol, 2011, 135(5): 750-752. DOI: 10.1309/AJCP8FX5CLPISSSK. ［5］ Anderson TJ, Atalay MK, Grand DJ, et al. Management of nodules with initially nondiagnostic results of thyroid fineneedle aspiration: can we avoid repeat biopsy?［J］. Radiology, 2014, 272(3): 777-784. DOI: 10.1148/radiol.14132134. ［6］ Yang F, Yi F, Zheng Z, et al. Charactreization of a carcinogenesisassociated long noncoding RNA［J］. RNA Biol, 2012, 9(1): 110-116. DOI: 10.4161/rna.9.1.18332. ［7］ Vriens MR, Weng J, Suh I, et al. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer［J］. Cancer, 2012, 118(13): 3426-3432. DOI: 10.1002/cncr.26587. ［8］ Keutgen XM, Filicori F, Crowley MJ, et al. A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration［J］. Clin Cancer Res, 2012, 18(7): 2032-2038. DOI: 10.1158/1078-0432.CCR-11-2487. ［9］ Huang Y, Liao D, Pan L, et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation［J］. Eur J Endocrinol,2013, 168(5): 675-681. DOI: 10.1530/EJE-12-1029. ［10］ Liu CG, Calin GA, Meloon B, et al. An oligonucleotide microchip for genomewide microRNA profiling in human and mouse tissues［J］. Proc Natl Acad Sci USA, 2014, 101(26): 9740-9744. DOI: 10.1073/pnas.0403293101. ［11］ Dettmer M, Vogetseder A, Durso MB, et al. MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas［J］. J Clin Endocrinol Metab, 2013, 98(1): E1-E7. DOI: 10.1210/jc.2012-2694. ［12］ Yu S, Liu Y, Wang J, et al. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma［J］. J Clin Endocrinol Metab, 2012, 97(6): 2084-2092. DOI: 10.1210/jc.2011-3059. ［13］ Moran VA, Perera RJ, Khalil AM, et al. Emerging functional and mechanistic paradigms of mammalian long noncoding RNAs［J］. Nucleic Acids Res, 2012, 40(14): 6391-6400. DOI: 10.1093/nar/gks296. ［14］ Wang Y, Guo Q, Zhao Y, et al. BRAFactivated long noncoding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma［J］. Oncol Lett, 2014, 8(5): 1947-1952. DOI: 10.3892/ol.2014.2487. ［15］ Rogounovitch TI, Bychkov A, Takahashi M, et al. The common genetic variant rs944289 on chromosome 14q13.3 associates with risk of both malignant and benign thyroid tumors in the Japanese population［J］. Thyroid, 2015, 25(3): 333-340. DOI: 10.1089/thy.2014.0431. ［16］翁侠, 洪晓明. LincRNAPVT1在甲状腺癌组织中的表达及意义［J］.实用肿瘤杂志, 2017, 32(1): 57-61. DOI: 10.13267/j.cnki.syzlzz.2017.01.014. ［17］ Johnsson P, Morris KV. Expanding the functional role of long noncoding RNAs［J］. Cell Res, 2014, 24(11): 1284-1285. DOI: 10.1038/cr.2014.104. ［18］ Sugishita Y, Kammori M, Yamada O, et al. Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression［J］. Ann Surg Oncol, 2014, 21(7): 2318-2325. DOI: 10.1245/s10434-014-3552-6. ［19］ Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a majr indicator of poor outcome in differentiated thyroid carcinomas［J］. J Clin Endocrinol Metab, 2014, 99(5): E754-E765. DOI: 10.1210/jc.2013-3734. ［20］ Patel MR, Stadler ME, Deal AM, et al. STT3A, C1orf24, TFF3: putative markers forcharacterization of follicular thyroid neoplasms from fineneedle aspirates［J］. Laryngoscope, 2011, 121(5): 983-989. DOI: 10.1002/lary.21736. ［21］ Im S, Yoo C, Jung JH, et al. Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: correlation with clinicopathological parameters and prognosis［J］. Int J Med Sci, 2013, 10(2): 133140. DOI: 10.7150/ijms.5500. ［22］ Bernstein HG, Dobrowolny H, Trübner K, et al. Differential regional and cellular distribution of TFF3 peptide in the human brain［J］. Amino Acids, 2015, 47(5): 1053-1063. DOI: 10.1007/s00726-015-1938-9. ［23］王维健, 政峰. TFF3和半乳糖凝集素3在甲状腺肿瘤鉴别诊断中的临床意义［J］. 同济大学学报: 医学版, 2016, 37(6): 115-119. DOI: 10.16118/j.1008-0392.2016.06.023. ［24］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012［J］. CA Cancer J Clin, 2012, 62(1): 10-29. DOI: 10.3322/caac.20138. ［25］ Jin L, Lloyd RV, Henry MR, et al. The diagnostic utility of combination of HMGA2 and IMP3 qRTPCR testing in thyroid neoplasms［J］. Appl Immunohistochem Mol Morphol, 2015, 23(1): 36-43. DOI: 10.1097/PAI.0000000000000031.

[1]	Gong Yan, Chen Honglei. Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer [J]. Journal of International Oncology, 2024, 51(3): 186-190.
[2]	Zhang Jinnan, Liu Bangqing, Li Jun, Liu Xiaohui. Research on BHLHE40 targets HMGA2 to reduce the sensitivity of thyroid cancer cells to cisplatin through activating the oxidative phosphorylation pathway [J]. Journal of International Oncology, 2023, 50(7): 398-406.
[3]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[4]	Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing. MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2 [J]. Journal of International Oncology, 2022, 49(4): 193-198.
[5]	Jin Jiahui, Chen Cunhai, Ma Xuezhen. Effects of radiation-associated miRNA in radiotherapy for breast cancer [J]. Journal of International Oncology, 2022, 49(12): 735-738.
[6]	Jing Wenjun, Zhao Wenwen, Feng Qingqing, Zhao Wenfei, Zhao Lili, Zhang Xue, Wei Hongmei. Molecular basis and clinical prospect of the miR-34 family for the treatment of gastric cancer [J]. Journal of International Oncology, 2022, 49(11): 681-686.
[7]	Li Jinhao, Wang Guidong, Li Xuefei, Liu Zilin, Meng Kailong. Clinical study of venous phase CT value in predicting central group lymph node metastasis of papillary thyroid carcinoma [J]. Journal of International Oncology, 2022, 49(10): 581-585.
[8]	Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin. Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis [J]. Journal of International Oncology, 2022, 49(1): 45-50.
[9]	Hong Anlan, Cao Meng, Wang Yan, Fang Fang. Research progress on lncRNAs as members of ceRNA network in melanoma [J]. Journal of International Oncology, 2022, 49(1): 61-64.
[10]	Wu Yuping, Zhang Xiaoyu, Lu Keyi. Mechanism of PD-L1 in thyroid carcinoma and its application in diagnosis and treatment [J]. Journal of International Oncology, 2021, 48(9): 560-563.
[11]	Feng Zhiping, Yang Chuanzhou, Chen Ting, Zhu Jialun, Liu Chao, Lyu Juan, Lu Jianmei, Deng Zhiyong. BRD4 inhibitor specifically inhibits the development of wild-type Kras differentiated thyroid carcinoma by regulating BRD4/miR-106b-5p/P21 axis [J]. Journal of International Oncology, 2021, 48(8): 463-472.
[12]	Liu Pei, Pu Jiaze, Huang Wen, Wang Fei. Expression differences of miR-200c, miR-19a and miR-155 in gefitinib sensitive and drug resistant NSCLC patients and their effects on prognosis [J]. Journal of International Oncology, 2021, 48(7): 409-414.
[13]	Wang Yang, Liu Qian, Long Hui, Wu Qingming. Research status of fecal detection for colorectal cancer markers [J]. Journal of International Oncology, 2021, 48(7): 441-444.
[14]	Cheng Yiming, Li Gang, Wang Zhenming, Lyu Qianwen, Li Shirong. Value of serum miR-196a-5p and miR-105-5p in differential diagnosis of benign and malignant pulmonary nodules [J]. Journal of International Oncology, 2021, 48(5): 282-286.
[15]	Deng Bo'er, Kong Weimin. Epigenetic research progress of endometrial cancer [J]. Journal of International Oncology, 2021, 48(3): 184-188.

RNA related markers of thyroid cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments